2017-03-08,OncoMed Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results
2017-03-02,OncoMed Announces Multiple Abstracts Related To Anti-TIGIT Program Accepted For Presentation At The American Association For Cancer Research Annual Meeting 2017
2017-03-01,OncoMed Pharmaceuticals To Report Fourth Quarter And Year End Financial Results On March 8, 2017
2017-02-13,OncoMed Enrolls First Patient In Phase 1b Clinical Trial Of Its Anti-DLL4/VEGF Bispecific Antibody In Patients With Platinum-Resistant Ovarian Cancer
2017-02-08,OncoMed Pharmaceuticals To Present At The BIO CEO And Investor And Leerink Global Healthcare Conferences
2017-02-08,Noteworthy Wednesday Option Activity: OMED, ZEN, FMI
2017-01-27,5 Stocks Under $10 That Could Rocket Higher Soon
2017-01-27,These 5 Stocks Under $10 Could Get Hot Soon
2017-01-20,OncoMed Initiates Enrollment Of Phase 1b Clinical Trial Of Brontictuzumab For The Treatment Of Metastatic Colorectal Cancer Patients
2017-01-05,OncoMed Announces Year-End Cash Balance And 2017 Outlook
2017-01-04,OncoMed Initiates Enrollment Of Phase 1b Clinical Trial Of Anti-DLL4/VEGF Bispecific Antibody As Second-line Treatment For Metastatic Colorectal Cancer Patients
2016-12-19,Noteworthy Monday Option Activity: OMED, NKTR, MNKD
2016-12-05,OncoMed Announces Departure Of Chief Medical Officer
2016-12-01,RSI Alert: OncoMed Pharmaceuticals (OMED) Now Oversold
2016-11-29,OncoMed Presents Initial First-in-Human Data For Anti-DLL4/VEGF Bispecific And Anti-RSPO3 At The 28th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-22,OncoMed Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-15,OncoMed To Present Clinical Data For Anti-RSPO3 And Anti-DLL4/VEGF Bispecific Antibody At The 28th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-01,OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results
2016-10-26,OncoMed Pharmaceuticals To Report Financial Results For The Third Quarter On Tuesday, November 1, 2016
2016-10-10,OncoMed Presents Interim Phase 1b Data For Ipafricept And Vantictumab In Pancreatic Cancer At The ESMO 2016 Congress
2016-09-30,Noteworthy Friday Option Activity: OMED, HLF, CIA
2016-09-29,OncoMed To Present Clinical Data For Wnt Inhibitors At The ESMO 2016 Congress
2016-09-01,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 YOSEMITE Clinical Trial Of Demcizumab In Pancreatic Cancer
2016-08-31,OncoMed Management To Present At Two Upcoming Investment Conferences
2016-08-30,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 PINNACLE Clinical Trial Of Tarextumab In Small Cell Lung Cancer
2016-08-23,OncoMed Pharmaceuticals Announces Closing Of Public Offering Including Exercise Of Underwriters' Right To Purchase Additional Shares
2016-08-18,Oversold Conditions For OncoMed Pharmaceuticals (OMED)
2016-08-18,OncoMed Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,OncoMed Pharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-15,Noteworthy Monday Option Activity: OMED, ISRG, STAA
2016-08-10,Short Interest In OncoMed Pharmaceuticals Moves 18% Higher
2016-08-09,OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results
2016-08-03,OncoMed Pharmaceuticals To Report Financial Results For The Second Quarter 2016 On Tuesday, August 9, 2016
2016-07-27,Commit To Purchase OncoMed Pharmaceuticals At $10, Earn 29.6% Annualized Using Options
2016-07-07,OncoMed Management To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
2016-06-28,5 Best-Positioned Biotech Stocks on Brexit Volatility
2016-06-06,OncoMed Management To Present At Two Upcoming Investment Conferences
2016-06-05,OncoMed Presents Phase 1b Data For First-in-Class Treatments In Ovarian, Breast And Lung Cancer At The 2016 ASCO Annual Meeting
2016-05-05,OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
2016-04-29,OncoMed Pharmaceuticals To Report Financial Results For The First Quarter 2016 On Thursday, May 5, 2016
2016-04-28,Commit To Purchase OncoMed Pharmaceuticals At $12.50, Earn 23% Annualized Using Options
2016-04-21,OncoMed Announces Clinical Data To Be Presented At The 2016 ASCO Annual Meeting
2016-04-20,OncoMed Presents Biomarker Research For Two Clinical Programs And Demcizumab Mechanism Data At The AACR Annual Meeting 2016
2016-04-19,OncoMed Presents GITRL-Fc Research At The AACR Annual Meeting 2016
2016-03-17,OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial For Demcizumab And Pembrolizumab (anti-PD1)
2016-03-16,OncoMed To Present Data At The American Association Of Cancer Research Annual Meeting 2016
2016-03-10,OncoMed Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results And 2016 Guidance
2016-03-04,OncoMed Pharmaceuticals To Report Fourth Quarter And Year-End 2015 Financial Results On Thursday, March 10, 2016
2016-03-02,7 Stocks Under $10 Making Big Breakout Moves
2016-02-22,OncoMed Presents Updated Phase 1b Data For Tarextumab In Small Cell Lung Cancer
2016-02-18,5 Stocks Under $10 Set to Soar
2016-02-08,OncoMed Provides Update On Tarextumab Phase 2 Programs
2016-02-04,OncoMed Pharmaceuticals To Present At Upcoming Investor Conferences
2016-01-25,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of OncoMed Pharmaceuticals, Inc.
2016-01-25,Noteworthy Monday Option Activity: OMED, ROCK, STAR
2016-01-25,OncoMed (OMED) Stock Plummets on Pancreatic Cancer Drug Trial Results
2016-01-25,OncoMed Provides Update On Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
2016-01-22,OncoMed Presents Updated Phase 1b Data For Demcizumab In First-Line Pancreatic Cancer At The Gastrointestinal Cancers Symposium
2016-01-15,Oversold Conditions For OncoMed Pharmaceuticals (OMED)
2016-01-11,Insider Trading Alert - MENT, TINY And OMED Traded By Insiders
2016-01-11,OncoMed Enrolls First Patient In Phase 1b Anti-RSPO3 Trial
2016-01-08,OncoMed Announces Publication Of Anti-RSPO Antibody Research In Cancer Research
2016-01-06,OncoMed Pharmaceuticals Appoints Perry Karsen To Board Of Directors
2016-01-05,OncoMed Achieves $72.5 Million In Milestone Payments From Celgene; Announces Year-End Cash Balance
2016-01-04,OncoMed Pharmaceuticals CEO To Present At The 34th Annual JPMorgan Healthcare Conference
2015-12-11,OncoMed Presents Vantictumab Biomarker Data At The San Antonio Breast Cancer Symposium (SABCS)
2015-11-12,OncoMed Pharmaceuticals To Present At Upcoming Investor Conferences
2015-11-09,Commit To Buy OncoMed Pharmaceuticals At $20, Earn 28.1% Annualized Using Options
2015-11-09,OncoMed Presents Data From Brontictuzumab, Vantictumab And Anti-DLL4/VEGF Bispecific Programs At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-11-07,OncoMed Presents Immuno-Oncology Data For Combined Blockade Of DLL4, VEGF And PD1 At The Society For Immunotherapy Of Cancer Annual Meeting
2015-11-05,OncoMed Pharmaceuticals Reports Third Quarter 2015 Financial Results
2015-11-04,OncoMed To Present Preclinical Data For The Combination Of Anti-DLL4/VEGF Bispecific Plus Anti-PD1 At The Society Of Immunotherapy For Cancer Meeting
2015-10-29,OncoMed Pharmaceuticals To Report Third Quarter 2015 Financial Results On Thursday, November 5, 2015
2015-10-28,Insider Trading Alert - LRCX, OMED And POOL Traded By Insiders
2015-10-27,OncoMed Announces Multiple Abstracts Accepted For Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-09-29,OncoMed To Present At The Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
2015-09-22,OncoMed Pharmaceuticals Becomes Oversold (OMED)
2015-09-16,OncoMed Presents Immuno-Oncology Data For GITRL-Fc Candidate At The Inaugural International Cancer Immunotherapy Conference
2015-09-09,OncoMed Pharmaceuticals Announces Presentation Of Tarextumab Small Cell Lung Cancer Data At The 16th World Conference On Lung Cancer
2015-08-31,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 ALPINE Clinical Trial Of Tarextumab In Pancreatic Cancer
2015-08-27,Notch3 Biomarker Results And Updated Data From OncoMed's Phase 1b/2 PINNACLE Clinical Trial Accepted For Presentation At The 16th World Conference On Lung Cancer
2015-08-10,OncoMed Pharmaceuticals Announces Second Quarter 2015 Financial Results And Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data
2015-08-07,Commit To Purchase OncoMed Pharmaceuticals At $17.50, Earn 13.5% Annualized Using Options
2015-08-05,OncoMed Pharmaceuticals To Report Second Quarter 2015 Financial Results On Monday, August 10, 2015
2015-07-31,5 Stocks Ready for Breakouts
2015-07-28,OncoMed Initiates Phase 1 Clinical Trial For Anti-RSPO3 Antibody
2015-07-08,OncoMed Pharmaceuticals Enters Oversold Territory (OMED)
2015-07-06,OncoMed To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-29,OncoMed Pharmaceuticals Appoints Rick Winningham To Board Of Directors
2015-06-01,OncoMed Presents Phase 1b Clinical Trial Data For Tarextumab In Small Cell Lung Cancer At The 2015 ASCO Annual Meeting
2015-06-01,OncoMed Presents Data From Phase 1b Trial Of Demcizumab In Pancreatic Cancer At The 2015 ASCO Annual Meeting
2015-06-01,OncoMed Presents Updated Demcizumab Data In Non-Small Cell Lung Cancer At The 2015 ASCO Annual Meeting
2015-05-28,OncoMed Pharmaceuticals To Review Key ASCO Data For Demcizumab And Tarextumab During Conference Call On Tuesday, June 2, 2015
2015-05-28,OncoMed To Present At Upcoming Investment Conferences
2015-05-22,Bearish Bets: Northwest Natural Gas Deflates
2015-05-21,Insider Trading Alert - OMED, ALQA And SNBC Traded By Insiders
2015-05-14,OncoMed To Present At UBS Global Healthcare Conference
2015-05-14,Ratings Changes Today
2015-05-07,OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results
2015-05-07,Commit To Buy OncoMed Pharmaceuticals At $17.50, Earn 15.8% Annualized Using Options
2015-05-04,OncoMed Pharmaceuticals To Report First Quarter 2015 Financial Results On Thursday, May 7, 2015
2015-05-04,OncoMed To Present At The Credit Suisse Antibody Day
2015-05-01,OncoMed Publishes Data On Tarextumab's Anti-Cancer Stem Cell Activity In Clinical Cancer Research
2015-04-29,OncoMed Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day
2015-04-23,OncoMed Pharmaceuticals To Webcast 2015 Research And Development Day On April 29, 2015
2015-04-22,OncoMed Initiates Dosing In Randomized Phase 2 Clinical Trial Of Demcizumab In Pancreatic Cancer Patients
2015-04-21,OncoMed Presents Data On Clinical And Preclinical Anti-Cancer Stem Cell Programs At American Association For Cancer Research Annual Meeting
2015-04-21,OncoMed Announces Abstracts Accepted For Presentation At The 2015 ASCO Annual Meeting
2015-04-16,OncoMed Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference
2015-04-09,OncoMed To Present At The Needham Healthcare Conference
2015-04-09,OncoMed To Present Clinical Data For Demcizumab At The European Lung Cancer Conference
2015-04-02,OncoMed And Lilly Enter Clinical Supply Agreement To Evaluate The Combination Of Demcizumab And Alimta(R) (pemetrexed For Injection) In Lung Cancer
2015-03-23,Ratings Changes Today
2015-03-20,Insider Trading Alert - CCNE, OMED And ALSN Traded By Insiders
2015-03-19,OncoMed To Present Data On Multiple Anti-Cancer Stem Cell Candidates At The American Association Of Cancer Research Meeting
2015-03-12,OncoMed Pharmaceuticals Reports Full Year And Fourth Quarter 2014 Financial Results And Recent Highlights
2015-03-03,OncoMed Pharmaceuticals To Report Full Year And Fourth Quarter 2014 Financial Results On Thursday, March 12, 2015
2015-02-05,Commit To Buy OncoMed Pharmaceuticals At $20, Earn 23.9% Annualized Using Options
2015-02-04,OncoMed Initiates Dosing In Phase 2 Clinical Trial Of Demcizumab For The Treatment Of Non-Small Cell Lung Cancer
2015-01-29,FDA Grants Orphan Drug Designations To OncoMed's Tarextumab For The Treatment Of Pancreatic And Small Cell Lung Cancer
2015-01-28,OncoMed Pharmaceuticals To Present At The BIO CEO And Investor And Leerink Global Healthcare Conferences In February
2015-01-22,Insider Trading Alert - ATSG, OMED And IMPV Traded By Insiders
2015-01-16,OncoMed Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium
2015-01-15,OncoMed Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors
2015-01-13,OncoMed To Present Clinical Data And Biomarker Analysis For Tarextumab At The 2015 Gastrointestinal Cancer Symposium
2015-01-12,OncoMed Pre-Announces 2014 Year-End Cash Balance And Provides 2015 Guidance
2015-01-08,Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic
2015-01-08,OncoMed Pharmaceuticals (OMED) Stock: Weak On High Volume Today
2015-01-07,OncoMed Pharmaceuticals To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2015-01-05,OncoMed Doses First Patient In Phase 1 Clinical Trial Of Novel Anti-DLL4/VEGF Bispecific Antibody
2014-12-15,OncoMed Pharmaceuticals Becomes Oversold (OMED)
2014-12-01,OncoMed Begins Patient Dosing In Phase 2 Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) In Small Cell Lung Cancer
2014-11-21,OncoMed Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The EORTC-NCI-AACR Symposium
2014-11-20,OncoMed Pharmaceuticals To Present At Piper Jaffray Healthcare Conference
2014-11-19,OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial Of Anti-Notch1 (OMP-52M51) In Oral Plenary Session At The 26th EORTC-NCI-AACR Symposium
2014-11-07,Commit To Purchase OncoMed Pharmaceuticals At $15, Earn 17.9% Annualized Using Options
2014-11-04,OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial And Operating Results
2014-11-03,OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent In The U.S.
2014-10-30,OncoMed To Present Clinical And Preclinical Data At The 26th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Meeting
2014-10-29,OncoMed To Announce Financial Results For The Third Quarter 2014 On Tuesday, November 4, 2014, After Close Of U.S.-Based Financial Markets
2014-10-10,Short Interest Expands By 13.4% For OMED
2014-10-07,OncoMed Pharmaceuticals To Present At The 13th Annual BIO Investor Forum
2014-09-30,OncoMed Pharmaceuticals Announces Selection Of First Small Molecule Product Candidate Targeting The Wnt Pathway Under Collaboration With Bayer Pharma AG
2014-09-29,OncoMed Presents Encouraging Data From Clinical Trials Of Tarextumab (Anti-Notch2/3) In Pancreatic Cancer And Small Cell Lung Cancer At The ESMO 2014 Congress
2014-09-28,OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety And Anti-Tumor Activity At ESMO
2014-09-23,4 Health Care Stocks Triggering Breakout Trades on Unusual Volume
2014-09-17,OncoMed To Present New And Emerging Data From Demcizumab (anti-DLL4, OMP-21M18) And Tarextumab (anti-Notch2/3, OMP-59R5) Clinical Studies At The European Society For Medical Oncology 2014 Congress
2014-09-04,FDA Removes Partial Clinical Hold On OncoMed's Ipafricept
2014-09-02,OncoMed Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2014-08-28,OncoMed Pharmaceuticals Announces Removal Of Partial Clinical Hold By The FDA For Vantictumab
2014-08-27,5 Stocks With Big Insider Buying
2014-08-22,OMED: Insiders vs. Shorts
2014-08-19,Ratings Changes Today
2014-08-11,Earnings Report Card for Small-Caps
2014-08-07,OncoMed Pharmaceuticals Announces Second Quarter 2014 Financial Results
2014-07-24,4 Biotech Stocks Breaking Out on Big Volume
2014-07-16,OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer
2014-07-02,OncoMed Pharmaceuticals Granted Broad FZD-Fc Composition-of-Matter And Use Patent In U.S.
2014-06-19,OncoMed Pharmaceuticals To Present At The 9th Annual JMP Securities Healthcare Conference
2014-06-18,OncoMed Provides Update On FZD8-Fc (OMP-54F28) Phase I Clinical Trials
2014-06-14,OncoMed Presents Data For Notch1 Diagnostic Assay At The 19th European Hematology Association Congress
2014-06-13,Vantictumab Placed On Partial Clinical Hold By FDA Following Voluntary Halt By OncoMed
2014-06-13,OncoMed Voluntarily Halts Enrollment And Dosing In Phase 1 Vantictumab And Fzd8-Fc Trials
2014-06-04,OncoMed To Present Data For Notch1 Program At The 19th European Hematology Association Congress
2014-05-28,OncoMed Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-14,OncoMed To Present Data From Three Clinical Studies At The 2014 ASCO Annual Meeting
2014-05-08,OncoMed Pharmaceuticals Announces First Quarter 2014 Financial Results
2014-05-02,OncoMed Receives Orphan Drug Designation From The FDA For Demcizumab In Pancreatic Cancer
2014-04-23,OncoMed Announces Abstracts Accepted At The 2014 ASCO Annual Meeting
2014-04-08,OncoMed Presents Data On Multiple Anti-Cancer Stem Cell Programs At American Association For Cancer Research Annual Meeting
2014-03-18,OncoMed Pharmaceuticals Announces Full Year And Fourth Quarter 2013 Financial Results
2014-03-06,OncoMed To Present Data On Anti-Cancer Stem Cell Candidates At The American Association Of Cancer Research Meeting
2014-02-28,OncoMed Pharmaceuticals To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-20,OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial For OMP-54F28 (Fzd8-Fc) With Carboplatin And Paclitaxel In Ovarian Cancer
2014-02-18,OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial For OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar(R)) In Hepatocellular Cancer
2014-02-03,OncoMed Pharmaceuticals Granted Fourth RSPO-LGR Pathway Patent In U.S.
2014-01-27,OncoMed Pharmaceuticals To Present At Two Investor Conferences In February
2014-01-17,OncoMed Pharmaceuticals Presents Data From The Phase 1b Portion Of The ALPINE Clinical Study Of OMP-59R5 In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium
2014-01-17,OncoMed Pharmaceuticals Presents Data From Demcizumab Phase 1b Clinical Study In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium
2014-01-13,OncoMed Pharmaceuticals Initiates First Phase 1b Clinical Trial Of OMP-54F28 (Fzd8-Fc) With Nab-Paclitaxel (Abraxane(R)) And Gemcitabine In Pancreatic Cancer
